• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin

tetano

Editor, Senior Moderator
J Virol. 2012 Aug 22. [Epub ahead of print]
Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin.
de Vries RP, Smit CH, de Bruin E, Rigter A, de Vries E, Cornelissen LA, Eggink D, Chung NP, Moore JP, Sanders RW, Hokke CH, Koopmans M, Rottier PJ, de Haan CA.
Source

Virology Division, Department of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.
Abstract

Recombinant soluble trimeric influenza A virus (IAV) hemagglutinin (sHA(3)) has proven an effective vaccine antigen against IAV. Here we investigated to what extent the glycosylation status of the sHA(3) glycoprotein would affect its immunogenicity. Different glycosylation forms of subtype H5 trimeric HA protein (sH5(3)) were produced by expression in insect cells and different mammalian cells, in the absence and presence of inhibitors of N-glycan modifying enzymes, or by enzymatic removal of the oligosaccharides. The following sH5(3) preparations were evaluated: (1) HA proteins carrying complex glycans produced in HEK293T cells, (2) HA proteins carrying Man(9)GlcNAc(2) moieties, expressed in HEK293T cells treated with kifunensine, (3) HA proteins containing Man(5)GlcNAc(2) moieties derived from HEK293S GnTI(-) cells, (4) insect cell-produced HA proteins carrying paucimannosidic N-glycans, and (5) HEK293S GnTI(-) cell-produced HA proteins treated with endoglycosidase H, thus carrying side chains composed of only a single N-acetylglucosamine each. The different HA glycosylation states were confirmed by comparative electrophoretic analysis and by mass spectrometric analysis of released glycans. The immunogenicity of the HA preparations was studied in chickens and mice. The results demonstrate that HA proteins carrying terminal mannose moieties induce significantly lower hemagglutination inhibition antibody titers than HA proteins carrying complex glycans or single N-acetylglucosamine side chains. The glycosylation state of the HA proteins did not affect, however, the breadth of the antibody response as measured by an HA1 antigen microarray. We conclude that the glycosylation state of recombinant antigens is a factor of significant importance when developing glycoprotein-based vaccines such as recombinant HA proteins.

PMID:
22915811
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22915811
 
Back
Top Bottom